INS and amyotrophic lateral sclerosis: While it is not clear if increases in urinary p75ECD in ALS match metabolic derangements that accompany disease progression (such as changes in energy metabolism, glucose uptake and insulin sensitivity), the introduction of p75ECD as a fluid biomarker in ALS provides an opportunity for the evaluation and possible co-development of metabolism-associated biomarkers.